Kleanthis Gabriel Xanthopoulos - 31 Mar 2026 Form 4 Insider Report for Connect Biopharma Holdings Ltd (CNTB)

Reporting relationship: Director
Issuer ticker: CNTB
Reported as of: 31 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Apr 2026, 16:27:54 UTC
Prior SEC filing: 16 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Lisa Peraza attorney-in-fact for Kleanthis Xanthopoulos

Key filing fact

Kleanthis Gabriel Xanthopoulos filed Form 4 for Connect Biopharma Holdings Ltd (CNTB) on 02 Apr 2026.

Key facts

This page summarizes Kleanthis Gabriel Xanthopoulos's Form 4 filing for Connect Biopharma Holdings Ltd (CNTB).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Apr 2026, 16:27.

Change

Previous filing in this sequence was filed on 16 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002115875 Primary reporting owner

Xanthopoulos Kleanthis Gabriel

Relationship: Director
Address: 3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO
Signature: /s/ Lisa Peraza attorney-in-fact for Kleanthis Xanthopoulos
Signature date: 02 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CNTB transaction

Ordinary Shares

Award

Transaction value
Shares: +2,816
Change %: +3.5%
Price: $0.000000^*
Shares after: 82,816
Date: 31 Mar 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Dr. Xanthopoulos elected to receive fully vested shares in lieu of a portion of cash compensation for his 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Dr. Xanthopoulos for his service as a director during the first quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares over the 30 consecutive trading days immediately preceding March 31, 2026, rounded down to the nearest whole share.